These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 26359124)

  • 1. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
    Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
    J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
    Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
    Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
    Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
    Mueller M; Schlosser E; Gander B; Groettrup M
    Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
    Zhang XQ; Dahle CE; Weiner GJ; Salem AK
    J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
    San Román B; Gómez S; Irache JM; Espuelas S
    J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
    Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
    Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
    [No Abstract]   [Full Text] [Related]  

  • 8. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
    Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
    J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
    Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
    Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
    Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
    Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
    Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
    Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antigen exposure in newborn piglets circumvents induction of oral tolerance in response to intraperitoneal vaccination in later life.
    Pasternak JA; Ng SH; Buchanan RM; Mertins S; Mutwiri GK; Gerdts V; Wilson HL
    BMC Vet Res; 2015 Mar; 11():50. PubMed ID: 25889479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
    Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
    J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles.
    Du G; Hathout RM; Nasr M; Nejadnik MR; Tu J; Koning RI; Koster AJ; Slütter B; Kros A; Jiskoot W; Bouwstra JA; Mönkäre J
    J Control Release; 2017 Nov; 266():109-118. PubMed ID: 28943194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
    Mathew S; Lendlein A; Wischke C
    Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled release microparticles for vaccine development.
    O'Hagan DT; Jeffery H; Roberts MJ; McGee JP; Davis SS
    Vaccine; 1991 Oct; 9(10):768-71. PubMed ID: 1759495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.